Pseudomonas exotoxin A antigen delivery platform (PE platform)

The Pseudomonas exotoxin A (PE) fusion platform is a biotechnological delivery system designed to channel exogenous antigens into the MHC class I presentation pathway, a process known as cross-presentation (Hung et al., 2001, Cancer Research). Pseudomonas exotoxin A, a 66 kDa protein from Pseudomonas aeruginosa, naturally utilizes a retrograde transport mechanism to move from the cell surface receptor LRP1 (CD91) through the Golgi to the endoplasmic reticulum (ER), where its translocation domain (Domain II) facilitates entry into the cytosol (Wedekind et al., 2001, J. Mol. Biol.; Kounnas et al., 1992, J. Biol. Chem.). By fusing a target antigen to a detoxified version of PE (e.g., PE38 or PE(ΔIII)), the antigen is effectively 'shuttled' into the cytosol, allowing it to be processed by the proteasome and presented on MHC class I molecules to activate cytotoxic CD8+ T cells (Liao et al., 2005, Cancer Research). This platform is primarily utilized in the development of therapeutic vaccines for cancer and chronic viral infections, such as those caused by human papillomavirus (HPV), where robust cellular immunity is required for clearance (Kim et al., 2007, Gene Therapy). While highly effective in preclinical models, challenges include the development of neutralizing anti-drug antibodies against the bacterial toxin scaffold and potential systemic toxicities like capillary leak syndrome (Pastan et al., 2006, Nat. Rev. Cancer).

Other names

PE-based fusion platformPseudomonas exotoxin A translocation systemPE-mediated antigen deliveryDetoxified Pseudomonas exotoxin A platformPE-fusion technology

The platform utilizes the translocation domain of Pseudomonas exotoxin A to facilitate the escape of fused antigens from the endosome or endoplasmic reticulum into the cytosol, where they are processed by the proteasome and loaded onto MHC class I molecules for presentation to CD8+ T cells (Hung et al., 2001).